PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2010 April 1.
Published in final edited form as:
PMCID: PMC2848475
NIHMSID: NIHMS126028

CONTRIBUTION OF HOST-DERIVED TISSUE FACTOR TO TUMOR NEOVASCULARIZATION

Abstract

Objective

The role of host-derived tissue factor (TF) in tumor growth, angiogenesis and metastasis has hitherto been unclear, and was investigated in this study.

Methods

We compared tumor growth, vascularity and responses to cyclophosphamide (CTX) of tumors in wild type (wt) mice, or in animals with TF levels reduced by 99% (low-TF mice).

Results

Global growth rate of three different types of transplantable tumors (LLC, B16F1 and ES teratoma), or metastasis were unchanged in low-TF mice. However, several unexpected tumor/context-specific alterations were observed in these mice, including: (i) reduced tumor blood vessel size in B16F1 tumors; (ii) larger spleen size and greater tolerance to CTX toxicity in the LLC model; (iii) aborted tumor growth after inoculation of TF-deficient tumor cells (ES TF-/-) in low-TF mice. TF-deficient tumor cells grew readily in mice with normal TF levels, and attracted exclusively host-related blood vessels (without vasculogenic mimicry). We postulate that this complementarity may result from tumor-vascular transfer of TF-containing microvesicles, as we observed such transfer using human cancer cells (A431) and mouse endothelial cells, both in vitro and in vivo.

Conclusions

Our study points to an important, but context-dependent role of host TF in tumor formation, angiogenesis and therapy.

INTRODUCTION

Several experimental studies point to the antitumor effects of genetic and pharmacological blockade of the coagulation system including tumor-cell associated tissue factor (TF) 1;2, and often through interference with angiogenesis 3-6. However, other reports suggest that TF expression by cancer cells is of little (or no) consequence for tumor aggressiveness 7;8. For instance, experiments with murine embryonic stem (ES) cells with either intact (TF+/-) or disrupted (TF-/-) TF gene originally led Toomey et al to conclude that subcutaneous teratomas could be efficiently generated irrespectively of the TF status of tumor forming (ES) cells 7. A possible explanation of this conundrum could lie in the observation that TF may be expressed by various subsets of host cells often present in the tumor mass, including, stromal fibroblasts, inflammatory cells and the endothelium, all likely involved in regulation of angiogenesis 9, but this possibility has not been explored directly.

The effects of TF on vascular cells could be mediated through localized procoagulant effects of this receptor, irrespectively of its cellular source, leading to the generation of factor Xa and thrombin, followed by the deposition of fibrin and activated platelets 2;10. However, the effects of TF could also be more cell autonomous in nature, and driven by changes in intracellular signaling 11. In this case the co-expression of TF and protease activated receptors (PARs) could trigger signals mediated by thrombin (via PAR-1), or by TF/VIIa complex 11-13, including interactions between the cytoplasmic tail of TF and PAR-2 receptor in endothelial cells 14. Interestingly, deletion of the latter domain in transgenic mice altered (increased) their vascular responses in the context of tumors and developing retina 14. However, the angiogenic consequences associated with the obliteration of the entire TF molecule in the host compartment of a growing tumor are still to be examined.

In this regard, studies on host-related TF have been hampered by the embryonic lethality associated with TF gene disruption in mice, and with limitations of the available mouse-specific pharmacological antagonists of this receptor. Moreover, such agents tend to target selectively some (procoagulant), but not all biological activities of TF 15, e.g. may not obliterate TF-dependent signaling 11. One way to circumvent these difficulties is to take advantage of a unique strain of mice, in which the endogenous mouse TF gene (mTF) is substituted with a human minigene (hTF) giving rise to the expression of a severely hypomorphic TF phenotype (low-TF mice) 16. Homozygous low-TF mice (mTF-/-/hTF+/+) are viable, but unlike their wild type (mTF +/+), or heterozygous (mTF+/-/hTF+/-) counterparts express only 1% of the expected TF activity, encoded exclusively by the hTF sequence 16. We chose low-TF mice to examine the effects of host-TF on tumor angiogenesis.

Here we show that the growth of three different types of TF-expressing transplantable tumors was unchanged in low-TF mice, as compared to that in their TF-proficient counterparts. However, host TF does exert a number of context-dependent effects, including on blood vessel size in some, but not all tumors. Importantly, in the absence of tumor-related TF the growth of tumors in low-TF mice was completely aborted. We propose that TF plays a crucial role in tumor formation, and it can be shared between tumor and host compartment through exchange of membrane microvesicles.

MATERIALS AND METHODS

Cells and culture conditions

Lewis Lung Carcinoma (LLC), B16F1 melanoma and A431 human squamous cell carcinoma cells were purchased from American Type Tissue Collection (ATCC, Manassas, VA, USA). The cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; HyClone, Logan, Utah, USA) supplemented with 10% Fetal Bovine Serum (FBS; Invitrogen, Carlsbad, CA, USA). Mouse brain endothelial cells (MBE) were cultured on 1% gelatin coated dishes in EGM2 medium, as previously described 17;18. The labeling of A431 cell surface and related microvesicles with the PKH26 dye (Sigma, San Diego, CA) was conducted as previously described 6;19. MTF+/- and TF-/- ES cells were generated as detailed elsewhere 7, as were the wild type ES cells (R1) and their LacZ (C16) and YFP (YC5)-tagged derivatives, a generous gift of Dr. Andras Nagy, University of Toronto 20. All ES cells were maintained on gelatinized (0.1%) culture plates in the presence of mitomycin C treated fibroblasts (MEFs; DR4 from American Tissue Culture Collection, Manassas, VA) containing 2ME, non essential amino acids, leukemia inhibitory factor (LIF/ESGRO, Millipore, Billerica, MA; 500 U), 15% pre-tested fetal bovine serum (Hyclone) and with frequent feeding and subculturing. The cells were passaged several times without MEFs before injection into mice 20.

Northern analysis

Expression of TF transcripts was analysed as described earlier 6. The membranes were examined using the Typhoon 9410 Phosphoimager (Amersham Biosciences) and autoradiographed.

Mice

Low-TF mice were described previously 16. For tumor studies the mice were backcrossed into either C57BL/6 (LLC, B16F1), or (ES-teratoma) severe combined immunodeficiency (SCID) background.

Tumor generation and analysis

Tumorigenic cells were collected and injected subcutaneously in 0.1 ml of phosphate buffered saline (PBS), at the following predetermined numbers: 7-10 × 105 (LLC), 2 × 106 (B16F1) and 107 (ES cells) under isoflurane anesthesia (1 – 3%). Tumor growth was monitored as described earlier 20. All in vivo experiments were conducted approved by the institutional Animal Care Committees at McMaster and McGill Universities and in accordance with the Canadian Council of Animal Care (CCAC) guidelines.

Therapy

Cyclophosphamide (CTX; Procytox, ASTA Medica, Ltd.) was used according to previously published maximal tolerated dose (MTD) and low dose/metronomic (LD) protocols 21. Under the MTD regimen the drug was injected at 150 mg/kg on days: 2, 4 and 6 post tumor cell inoculation, and then on days: 23, 25 and 27. Increase in mortality occurred after the first round of injections. For metronomic (LD) therapy the drug was injected at the dose of 150 mg/kg on day 2 post tumor inoculation and then daily at 25 mg/kg 21. A monoclonal anti-human TF antibody (TF8-5G9; Centocor Inc.; 5 mg/kg) or vehicle was injected intraperitoneally into low-TF mice (hTF) harboring LLC tumors (mTF) 3 times a week beginning on day 2 post tumor cell inoculation.

Experimental metastasis

A single cell suspension of 105 LLC cells/0.2 ml PBS was injected into the pre-warmed dilated lateral tail veins of the respective wild type, or low-TF syngeneic C56BL/6 mice, as indicated. Mice were sacrificed after 28 days and autopsied. Lungs were excised preserved in Bouin’s fixative, and surface nodules were counted under a dissecting microscope, as described 22.

Tissue staining

Microvasculature of tumors was assessed by immunostaining for endothelial (CD31/PECAM; CD105/endoglin), or pericyte markers (αSMA), as described elsewhere 23.

Data analysis

The experiments were repeated 2-5 times, mostly 3 times, with similar results. The number of experimental mice per group in all in vivo studies varied between 4-10 for each experiment. The results were expressed as mean +/- SD for each group. Unpaired Student t tests were used to examine the differences between groups. Probability values <0.05 were considered significant unless otherwise stated.

RESULTS

Host TF and blood vessel patterning in melanoma

In syngeneic mice, B16F1 mouse melanoma cells form rapidly growing tumors containing cuffs of viable malignant parenchyma clustering around distinctly large (15-30μm) blood vessels, in which endothelial layers are covered with well-differentiated pericytes, as determined by staining for CD31/PECAM (or CD105/endoglin) and alpha smooth muscle actin (αSMA), respectively (Fig. 1A). These host cells are known to express TF 13. Injection of B16F1 cells into mice with intact TF levels (mTF+/-) or into their hypomorphic, low-TF counterparts resulted in indistinguishable rate of tumor formation (Fig. 1B), however the tumor vascular microarchitecture has undergone a significant rearrangement (Fig. 1C). Thus, in low-TF mice tumor blood vessels were still covered with pericytes, but for the most part were considerably smaller in size (mostly < 15μm in diameter) than those in TF-proficient mice (both mTF+/+ and mTF+/-).

Figure 1
Growth and vascular patterning of B16F1 melanoma in low-TF mice

Unchanged, growth, vascularity and metastasis of Lewis Lung Carcinoma (LLC) in low-TF mice

Similarly to B16F1 melanoma, LLC cells form aggressive tumors in vivo, but with vastly different vascular patterns. A defining feature in this case is the absence of large vessels and a dense network of small capillaries (<15μm), largely devoid of SMA-reactive pericytes (Fig. 2A). While the TF content of LLC tumors increases in vivo, possibly with some contribution of host TF (Fig. 2B), the latter does not influence LLC progression or angiogenesis, as tumor growth, experimental metastasis and vascular patterns were virtually identical in wild type (mTF+/+), heterozygous (mTF+/-) and low-TF mice (Fig. 2CD, data not shown). Tumor growth remained unchanged even when tumor-bearing, low-TF mice were treated with an anti-human TF antibody (TF8-5G9), which would selectively obliterate the residual host TF (encoded by the hTF transgene), but not tumor/LLC-related (mouse) TF 16 (Fig. 2C).

Figure 2
Unchanged growth and metastasis of LLC tumors in low-TF mice

Host-related TF modulates toxic side effects of cyclophosphamide

Anti-cancer agents often trigger procoagulant events 24. We asked whether host TF may play a role in this context, or in responses to other prototypic therapies such as administration of cyclophosphamide (CTX) at maximal tolerated doses (MTD), or at antiangiogenic/metronomic, low doses (LD), both previously validated in the LLC model 21. As shown in Fig. 3A, the responses of LLC tumors to MTD or LD protocols of CTX were unaffected by the host TF status. Interestingly, MTD therapy led to some mortality, but only in TF-proficient (mTF+/-) tumor bearing mice and not in their low-TF counterparts (Fig. 3B). Moreover, we observed that untreated low TF (SCID) mice exhibit markedly larger spleens than their mTF+/+ or mTF+/- controls (Fig. 3CD). This was also the case in LLC tumor bearing mice, where low TF hosts contained more extensive lymphocytic infiltrates in areas surrounding white pulp. While CTX treatment reduced spleen size and cellularity in all mice, low TF mice retained greater amounts of spleen mass and white pulp nodules (Fig. 3E-I). Interestingly, these mice also had reduced fibrin deposition in their kidney (not shown). This may suggest that low levels of host TF may have a protective role against some of the side effects of anticancer therapy, likely through a combination of coagulation-dependent and hematopoietic effects that remain to be elucidated.

Figure 3
Unchanged antitumor responses, diminished chemotherapy-related mortality and abnormal spleens in low-TF mice harboring LLC tumors

Host TF expression is essential for growth of TF-deficient teratomas

In agreement with the aforementioned results subcutaneous injection of TF-expressing and tumorigenic embryonic stem (ES) cells led to unperturbed formation of aggressive and angiogenic teratomas in both wild type and low-TF mice (Fig. 4)23. In this case the mice were backcrossed to the SCID background to avoid immune rejection. It is of note that the model of ES teratoma afforded us a unique opportunity to interrogate TF depletion in both the host and tumor cell compartments simultaneously, e.g. by including TF-/- ES cells 7 and low-TF mice. Thus, we observed that both TF+/- and TF-/- ES cells grew as vascular teratomas in SCID mice with wild type levels of TF7. Remarkably, this process was selectively aborted in the case of TF-/- ES cells (but not TF+/- cells) injected into low-TF SCID mice (Fig. 4B). This result suggests that TF is essential for the malignant teratoma growth to occur, and this requirement can be met through TF contribution by either tumor, or host cells.

Figure 4
Complementary roles of host- and tumor-related tissue factor during formation of ES cell derived teratomas

ES cell-derived teratomas recruit host blood vessels

The aforementioned result is novel and potentially important. However, totipotential capacity of ES cells to differentiate 25 may imply that tumor blood vessels may in this case originate from tumor (ES) cells and not through recruitment of host endothelium, a phenomenon known as vasculogenic mimicry 26. Indeed, ES teratomas contain complex mixtures of histological elements including abnormal capillaries (Fig. 4C-E). To unequivocally distinguish tumor (ES) and host (mouse)-derived elements we used several molecular tags, including: yellow and green fluorescent proteins (YFP and GFP), as well as beta galactosidase (LacZ; Fig. 4C-H). Thus, TF-proficient (mTF+/+) ES cells (R1) tagged with LacZ were injected into untagged SCID mice, and we determined that all tumor-associated, CD31-positive endothelial cells originated from the LacZ-negative host compartment (Fig. 4F). We also generated teratomas from unlabelled ES cells that were injected into YFP/SCID mice harboring a constitutively expressed YFP transgene23. Again, staining for CD105 and YFP revealed dual positivity (host origin) of all tumor-associated blood vessels (Fig. 4G). Finally, YFP-labeled ES cells were used to generate tumors in untagged SCID mice and, again, we observed essentially no overlap between YFP and CD105 staining, except for a solitary blood vessel found in one section (Fig. 4H). This enforces the notion that ES teratomas, like many other cancers, rely on recruitment of the host-derived vasculature, which may serve as a source of TF to support growth of TF-/- tumors shown in Fig. 4B

Endothelial cell uptake of tumor-related TF-containing microvesicles

The aforementioned experiments (Fig. 4B) raise the possibility that TF activity may be shared between tumor and host cell compartments. One mechanism by which this could occur is through intercellular exchange of TF containing microvesicles (MVs) 27-29. To test this, we employed the human epithelial carcinoma cell line, A431, which produces ample amounts of TF (Fig. 5A), which is also shed into conditioned medium as membrane MVs 28. To test, whether this material could, indeed, be transferred to endothelial cells, the membranes of A431 cells were labeled with the fluorescent dye (PKH26) and their conditioned medium (containing MVs) was incubated with TF-negative mouse brain endothelial cells (MBEs). This led to a lasting acquisition by the latter cells of PKH26 fluorescence, human TF antigen expression (not shown) and TF-dependent procoagulant activity (Fig. 6AB), all derived from A431 tumor cells. These changes did not occur when A431-derived material was depleted from the MV fraction by high-speed centrifugation 28. Moreover, host blood vessels in A431 xenografts in SCID mice were positive for both human TF (Fig. 5 E-G) and endothelial markers (CD105), suggesting the intercellular transfer of TF taking place in vivo (Fig. 5H).

Figure 5
Microvesicle-mediated sharing of TF between tumor and endothelial cells

DISCUSSION

In this study we report several new findings related to the role of host TF in tumor angiogenesis and progression. Notably, we provide evidence that TF expression may be essential for tumorigenesis, at least in some settings, since a simultaneous depletion of this receptor from both tumor and host compartments led to a complete arrest of tumor formation. The nature of this effect remains presently unknown, but may include thrombin-dependent and/or independent, essential effects of TF on hemostasis, and/or on signaling in endothelial, stromal and/or tumor cells 11;13. In spite of this uncertainty, our results may reconcile the long standing controversy, as to whether TF contributes to primary tumor growth and angiogenesis 3-6;30;31, or is irrelevant for these processes 7;8. Using the same TF-/- ES cell lines 7 that have originally led to the latter notion we demonstrated that the removal of TF from cancer cells may, at least in some cases, be insufficient to block tumor formation, notably due to compensatory effects of the host-derived TF (and vice versa). We propose that this TF ‘sharing’ between tumor and host compartments could occur through the exchange of TF containing microvesicles, as recently described for inflammatrory cells and platelets 29. In particular, we suggest that such TF transfer could contribute to procoagulant and proangiogenic reprogramming of endothelial cells in TF expressing tumors 9 (Fig 5E). In addition, our study provides an important validation of the widely used ES teratoma model, by documenting the absence of ES-derived blood vessels (vasculogenic mimicry) in these tumors.

Unlike ES cells, many cancer cell types express TF under influence of oncogenic alterations 6. We postulate that in such a context tumor-derived TF may assume a dominant role in tumorigenesis and can be targeted therapeutically, as recently demonstrated by Versteeg 32 and others 3;6;33. In these settings host-related TF makes a minimal quantitative contribution to local growth or metastasis, as documented by our experiments with several mouse tumor models (LLC, B16F1).

Interestingly, low levels of host TF led to qualitative re-patterning of the tumor microvasculature in B16F1 melanoma. We suggest that lack of similar effects in other tumors tested, is due to their a priori small caliber vasculature. It is unclear how host TF may impact blood vessel patterning. While thrombin and PAR-1 were implicated as regulators of vascular development 12;13, our injections of B16F1 cells into PAR-1-/- mice did not recapitulate the vascular patterns observed in low-TF mice (unpublished observation). While tumors in low-TF mice were of unchanged size, it is possible that vascular re-patterning may influence angiogenic pathways in a qualitative manner, and impact other vascular aspects of tumourigenesis, such as metastasis and therapeutic responses.

We were intrigued by the partial protection of LLC tumor bearing, low-TF mice from the toxicity of high doses (MTD) of CTX. This effect was unlikely due to a differential drug distribution, pharmacodynamics, or direct toxicity against tumor cells. In this regard, prothrombotic effects of anticancer chemotherapeutics are well established, including in the clinic 2;34. These events may be attributed to endothelial injury 35;36, suppression of the protein C pathway 24, upregulation of TF and decrease in levels of the tissue factor pathway inhibitor (TFPI)37. Indeed, we observed a lower fibrin deposition in kidneys of CTX-treated tumor bearing low-TF mice (data not shown). These mice demonstrated larger spleens containing greater reserves of lymphocytic cells, relative to their wild type counterparts. This finding may suggest a hitherto unappreciated role of TF in modulating hematopoietic toxicity of CTX.

Collectively, our findings reveal several novel properties of host TF. We suggest that a complex role of this receptor in tumor growth, angiogenesis, vascular patterning and drug toxicity has been previously obscured by exclusion of host TF from experimental studies. We observed that the effects of host-related TF are highly context dependent and different in tumors driven by aberrant differentiation (teratoma) or genetic aberrations (mouse melanoma, lung carcinoma). Therefore, defining a universal role for TF in cancer may prove elusive and targeting this receptor in various tumor settings may require a better understanding of cellular sources of TF and their specific contributions to the malignant process. Still, our study suggests that TF, in its cell-associated and microvesicular forms, may represent an attractive anticancer target, at least in some settings, especially as a regulator of tumor growth and/or modulator of anticancer drug toxicity.

Acknowledgments

This work was supported by operating grants to J.R. from the Canadian Cancer Society (CCS). JR is a recipient of the Jack Cole Chair in Pediatric Oncology at McGill University. JIW holds the Canada Research Chair in Thrombosis and the HSFO/JF Mustard Chair in Cardiovascular Research and is PI on the Team Grant from Canadian Institutes of Health Rresearch, which contributed some funds. We thank our colleagues, especially to Dr Petr Klement, for their feedback and our families for their inexhaustible support and patience.

Footnotes

Disclosures: JLY, LM, CM, JL, GB, JIW – none; NM – NIH grant pending; JR - CCS grant (M), Nuvelo – honorarium (m), NIH grant consultantship (m); M >$10,000, m<$10,000.

References

1. Dvorak FH, Rickles FR. Malignancy and Hemostasis. In: Coleman RB, Marder VJ, Clowes AW, George JN, Goldhaber SZ, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Company Williams & Wilkins; 2006. pp. 851–873.
2. Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb. 2006;35:103–110. [PubMed]
3. Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R, Stern DM, Nawroth PP. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 1994;94:1320–1327. [PMC free article] [PubMed]
4. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SG, Pribluda VS. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res. 2003;63:2997–3000. [PubMed]
5. Ngo CV, Picha K, McCabe F, et al. CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007;120:1261–1267. [PubMed]
6. Yu JL, May L, Lhotak V, Shahrzad, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005;105:1734–1741. [PubMed]
7. Toomey JR, Kratzer KE, Lasky NM, Broze GJ., Jr Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci U S A. 1997;94:6922–6926. [PubMed]
8. Palumbo JS, Talmage KE, Massari JV, LaJeunesse CM, Flick MJ, Kombrinck KW, Jarouskova M, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood. 2007;110:133–141. [PubMed]
9. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med. 1996;2:209–215. [PubMed]
10. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124:58S–68S. [PubMed]
11. Ruf W. Redundant signaling of tissue factor and thrombin in cancer progression? J Thromb Haemost. 2007;5:1584–1587. [PubMed]
12. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost. 2005;3:1800–1814. [PubMed]
13. Mackman N, Tilley RE, Key NS. Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arterioscler Thromb Vasc Biol. 2007 [PubMed]
14. Belting M, Dorrell MI, Sandgren S, Aquilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10:502–509. [PubMed]
15. Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of Tissue Factor.Factor VIIa for anticoagulant therapy. Curr Med Chem. 2004;11:2275–2290. [PubMed]
16. Parry GC, Erlich JH, Carmeliet P, Luther T, Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest. 1998;101:560–569. [PMC free article] [PubMed]
17. Hegmann EJ, Bauer HC, Kerbel RS. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res. 1992;52:6969–6975. [PubMed]
18. Klement H, St Croix B, Milsom C, May LJ, Guo Q, Yu JL, Klement P, Rak J. Atherosclerosis and Vascular Aging as Modifiers of Tumor Progression, Angiogenesis, and Responsiveness to Therapy. Am J Pathol. 2007;171:1342–1351. [PubMed]
19. Kalas W, Yu JL, Milsom C, Rosenfeld J, Benezra R, Bornstein P, Rak J. Oncogenes and Angiogenesis: Down-regulation of Thrombospondin-1 in Normal Fibroblasts Exposed to Factors from Cancer Cells Harboring Mutant Ras. Cancer Res. 2005;65:8878–8886. [PubMed]
20. Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. Am J Pathol. 2001;158:1325–1334. [PubMed]
21. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003;100:12917–12922. [PubMed]
22. Aslakson CJ, Rak JW, Miller BE, Miller FR. Differential influence of organ site on three subpopulations of a single mouse mammary tumor at two distinct steps in metastasis. Int J Cancer. 1991;47:466–472. [PubMed]
23. Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. EMBO J. 2003;22:4091–4102. [PubMed]
24. Mewhort-Buist TA, Liaw P, Patel S, Atkinson HM, Berry LR, Chan AK. Treatment of endothelium with the chemotherapy drug vincristine affects protein C generation in newborn plasma to a greater degree than in adult plasma. Thromb Res. 2008;122:418–426. [PubMed]
25. Feraud O, Cao Y, Vittet D. Embryonic stem cell-derived embryoid bodies development in collagen gels recapitulates sprouting angiogenesis. Lab Invest. 2001;81:1669–1681. [PubMed]
26. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer. 2003;3:411–421. [PubMed]
27. Giesen PL, Rauch U, Bohrmann B, Kling D, Rogue M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96:2311–2315. [PubMed]
28. Yu JL, Rak JW. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost. 2004;2:2065–2067. [PubMed]
29. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood. 2005;106:1604–1611. [PubMed]
30. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci U S A. 1999;96:8663–8668. [PubMed]
31. Zhao J, Aguilar G, Deitcher SR, Funk WD, Abo A. rNAPc2, a novel inhibitor of tissue factor/factor VIIa complex, suppresses lung metastasis and synergizes with 5-FU or bevacizumab in mouse models of colorectal cancer [abstract] Blood. 2006;108:32I.
32. Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008;111:190–199. [PubMed]
33. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in CD133-positive cancer cells. J Thromb Haemost. 2007;5:2550–2552. [PubMed]
34. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, DePauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988;318:404–407. [PubMed]
35. Kuenen BC, Levi M, Meijers JC, Kakkar AK, Van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol. 2002;22:1500–1505. [PubMed]
36. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007;7:475–485. [PubMed]
37. Ma L, Francia G, Viloria-Petit A, Hicklin D, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 2005;65:5365–5373. [PubMed]